Drug Profile
Tyrosine kinase inhibitor oral - OV SPV2
Alternative Names: TKI - OV SPV2Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; OV-SPV2
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer